We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




World's Smallest Heart Pump Helps Cardiologists Support High-Risk Patients during Complex Procedures

By HospiMedica International staff writers
Posted on 08 Jun 2023

Patients suffering from coronary artery disease often undergo a catheterization procedure to clear blocked arteries that supply the heart, with the intent of enhancing their quality of life and decreasing the risk of heart attacks. More...

However, patients with more severe conditions may experience instability during the coronary intervention, thus making them high-risk patients. For such patients, mechanical circulatory support during the procedure is beneficial to maintain systemic blood pressure and ensure the perfusion of essential organs, including the heart itself. Given that the support duration for such a case is typically short (up to 6 hours), with patients becoming mobile shortly after the procedure, it's crucial to minimize the device insertion profile to reduce vascular access complications. To address this, new technology has now miniaturized a robust blood pump to fit an 8 Fr delivery system, the smallest crimping profile for any device of its kind.

Magenta Medical’s (Kadima, Israel) percutaneous Elevate heart pump can be inserted over a guidewire through commercially available 10 Fr introducer sheaths that necessitate a small groin puncture. The pump's flow can be adjusted based on the patient's clinical situation, offering up to 5 L/min of mean flow, making it the most powerful pump in its class. The FDA has granted the Elevate device Breakthrough Device Designation for two indications - high-risk percutaneous coronary intervention (HR-PCI) and cardiogenic shock. Magenta has started the initial phase of its FDA-approved Early Feasibility Study with the Elevate percutaneous Left Ventricular Assist Device (pLVAD) for the HR-PCI indication. The FDA has approved the Elevate Early Feasibility Study to evaluate the safety and feasibility of the Elevate system in providing temporary mechanical circulatory support during HR-PCI procedures. This study marks the first step in a clinical program designed to secure approval for the device in the US for this indication.

"Magenta is proud to partner with top cardiology centers in the United States to further the validation of its technology and provide cardiologists with a powerful tool to support their high-risk patients during complex procedures," said Dr. David Israeli, CEO of Magenta Medical. "We are looking forward to a speedy recruitment process and favorable study outcomes that would allow us to take the next step in the clinical program towards ultimate market approval."

Related Links:
Magenta Medical


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Multifunctional Patient Floor Lift
Maxi Move 5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.